missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human BCAS3 (aa 799-883) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (96%), Rat (96%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-62602 (PA5-62602. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
BCAS3 is physically associated with histone H3 and histone acetyltransferase complex protein P/CAF (p300/CBP-associated factor) and possesses histone acetyltransferase activity. In breast cancer, several chromosomal sites frequently undergo amplification, implicating the location of genes important for tumor development and progression.
Specifications
Specifications
| Accession Number | Q9H6U6 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 54828 |
| Name | Human BCAS3 (aa 799-883) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 1500019F07Rik; 2610028P08Rik; AU021018; BC028339; Bcas3; BCAS3, microtubule associated cell migration factor; BCAS4/BCAS3 fusion; breast carcinoma amplified sequence 3; breast carcinoma amplified sequence 4/3 fusion protein; breast carcinoma-amplified sequence 3; Breast carcinoma-amplified sequence 3 homolog; GAOB1; K20D4; MAAB; Maab1 protein; metastasis associated antigen of breast cancer; protein Maab1; protein rudhira; RGD1560788; Rudhira |
| Common Name | BCAS3 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction